DONAFENIB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H16ClF3N4O3
Molecular Weight	467.843
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DONAFENIB

Structure Search

SMILES

[2H]C([2H])([2H])NC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1

InChI

InChIKey=MLDQJTXFUGDVEO-FIBGUPNXSA-N

InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3

HIDE SMILES / InChI

Molecular Formula	C21H16ClF3N4O3
Molecular Weight	467.843
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 12:08:09 UTC 2023` Edited by `admin` on `Sat Dec 16 12:08:09 UTC 2023`
Record UNII	41XGO0VS1U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DONAFENIB

Common Name

English

4-(4-((((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)AMINO)CARBONYL)AMINO)PHENOXY)-N-(METHYL-D3)-2-PYRIDINECARBOXAMIDE

Systematic Name

English

CM-4307

Code

English

Donafenib [WHO-DD]

Common Name

English

2-PYRIDINECARBOXAMIDE, 4-(4-((((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)AMINO)CARBONYL)AMINO)PHENOXY)-N-(METHYL-D3)-

Systematic Name

English

4-(4-((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)CARBAMOYLAMINO)PHENOXY)-N-(TRIDEUTERIOMETHYL)PYRIDINE-2-CARBOXAMIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C129825

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

NCI_THESAURUS

C2336

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

Code System Code Type Description

CAS

1130115-44-4

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

PRIMARY

PUBCHEM

25191001

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

PRIMARY

SMS_ID

100000183796

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

PRIMARY

NCI_THESAURUS

C118294

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

PRIMARY

DRUG BANK

DB15414

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

PRIMARY

MANUFACTURER PRODUCT INFORMATION

DONAFENIB

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

PRIMARY

MedKoo CAT NO.: 206144; Description: Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC). (Last update: 8/21/2015).

EPA CompTox

DTXSID90648995

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

PRIMARY

FDA UNII

41XGO0VS1U

Created by admin on Sat Dec 16 12:08:09 UTC 2023 , Edited by admin on Sat Dec 16 12:08:09 UTC 2023

PRIMARY

Related Record Type Details


					F3C1QUT2IS

DONAFENIB MESYLATE

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					41XGO0VS1U

DONAFENIB

ACTIVE MOIETY

Comments:

Official Title: Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial Purpose: Donafenib versus sorafenib for advanced hepatocellular cancer.


					41XGO0VS1U

DONAFENIB

ACTIVE MOIETY

Comments:

Drug: Donafenib(Primary); Indication: Colorectal cancer; Focus: Adverse reactions; Sponsor: Suzhou Zelgen Biopharmaceuticals; Most Recent Events: 04 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov., 07 Jul 2015 New trial record